BiondVax Pharmaceuticals Universal Flu Vaccine Pivotal Phase 3 Study Results by End October
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ’s pivotal Phase 3 trial in Europe was completed in June 2020 and the analysis of the results are expected
WizeCare Smart Physical Therapy Homecare Co to Raise $1M via Crowd Funding
You can participate in the WizeCare crowdfunding campaign https://pipelbiz.com/Campaign/52785. Concerns about health and safety in the face of the coronavirus pandemic have seen many clinics
Visibly Impaired Read More Efficiently than the Sighted via OrCam’s Breakthrough!
Jerusalem-based OrCam Technologies announced the US release of a new, voice-activated, interactive Smart Reading feature providing users who are blind, visually impaired, or have reading
BrainsWay Receives FDA Clearance for Ending Smoking Addiction in Adults
BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, has received 510(k) clearance from the U.S. Food
Concenter BioPharma Successfully Uses Crowdfunding to Finance Its Pill To End Diabetes!
Concenter BioPharma has raised $407 K (as of August 24 1.3 Million NIS) in just ten days using the PipelBiZ Crowdfunding Platform! Concenter Biopharma launched
Nanox raises $165.2m in Nasdaq IPO!
Congratulations to Ran Poliakine! The largest-ever IPO of an early stage Israeli medical technology company was completed at a company valuation of $800 million! Israeli
Alternative Meat Company SavorEat Raises $4.75 M
SavorEat announced that it raised Funds from The Mor and Meitav Dash investment houses will invest $3 million, and $1.75 million was raised from the
Kamada’s COVID Antibody Drug Small Trial, a World 1st, gets Flying Start at Hadassah in Jerusalem
The world’s first clinical trial for a coronavirus drug made from antibodies got off to a promising start at the Hadassah hospital in Jerusalem, with
Will Nanox be the Next Israeli Hit on Nasdaq?
NANO-X IMAGING LTD , an innovative medical imaging technology company, has secured over $110M in crossover equity investments from global investors since December 2019. Funds
